Trajenta

Trajenta

linagliptin

Manufacturer:

Boehringer Ingelheim

Distributor:

Metro Drug
Concise Prescribing Info
Contents
Linagliptin
Indications/Uses
As monotherapy in adult patients w/ type 2 DM to improve glycemic control in conjunction w/ diet & exercise, or as add-on to metformin, sulfonylureas, thiazolidinediones, insulin (w/ or w/o metformin &/or pioglitazone &/or sulfonylureas) or metformin + sulfonylureas or metformin + SGLT2 inhibitors.
Dosage/Direction for Use
Administration
May be taken with or without food.
Contraindications
Special Precautions
Patients w/ type 1 diabetes or treatment of diabetic ketoacidosis. Discontinue if pancreatitis or bullous pemphigoid is suspected. Hypoglycemia. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Hypoglycemia. Angioedema, urticaria; rash, bullous pemphigoid; mouth ulceration.
Drug Interactions
Decreased steady-state AUC, Cmax, & DPP-4 inhibition at trough w/ rifampicin.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BH05 - linagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Trajenta FC tab 5 mg
Packing/Price
30's (P1,320.5/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in